ImageneBio, Inc. Revenue
ImageneBio, Inc. (IMA) reported Revenue of $800.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- ImageneBio, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $0.00.
- ImageneBio, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ImageneBio, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $0.00.
- ImageneBio, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $800.00K.
- ImageneBio, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $800.00K, a 77.14% decline from fiscal 2024.
- ImageneBio, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $3.50M, a 61.79% decline from fiscal 2023.
- ImageneBio, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $9.16M, a 41.35% decline from fiscal 2022.
- ImageneBio, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $15.62M, a 49.59% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $800.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $800.00K 10-Q · filed 2025-11-12 | $800.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $800.00K 10-Q · filed 2026-08-05 | $800.00K derived: sum of 3 quarters · filed 2026-08-05 | $4.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $800.00K 10-Q · filed 2026-05-07 | $800.00K derived: sum of 2 quarters · filed 2026-05-07 | $4.30M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $3.50M derived: sum of 2 quarters · filed 2026-03-10 | $3.50M 10-K · filed 2026-03-10 | |
| 2024-09-30 | $3.50M 10-Q · filed 2025-11-12 | $3.50M 10-Q · filed 2025-11-12 | ||
| 2023-12-31 | $659.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.84M derived: sum of 2 quarters · filed 2025-03-06 | $3.85M derived: sum of 3 quarters · filed 2025-03-06 | $9.16M 10-K · filed 2025-03-06 |
| 2023-09-30 | $1.19M 10-Q · filed 2024-11-07 | $3.19M derived: sum of 2 quarters · filed 2024-11-07 | $8.50M 10-Q · filed 2024-11-07 | $13.95M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $2.00M 10-Q · filed 2024-08-08 | $7.32M 10-Q · filed 2024-08-08 | $12.77M derived: sum of 3 quarters · filed 2024-08-08 | $19.17M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $5.31M 10-Q · filed 2024-05-13 | $10.76M derived: sum of 2 quarters · filed 2024-05-13 | $17.16M derived: sum of 3 quarters · filed 2024-05-13 | $17.55M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $5.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $11.85M derived: sum of 2 quarters · filed 2024-03-12 | $12.23M derived: sum of 3 quarters · filed 2024-03-12 | $15.62M 10-K · filed 2024-03-12 |
| 2022-09-30 | $6.40M 10-Q · filed 2023-11-09 | $6.78M derived: sum of 2 quarters · filed 2023-11-09 | $10.17M 10-Q · filed 2023-11-09 | $30.39M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $382.00K 10-Q · filed 2023-08-10 | $3.77M 10-Q · filed 2023-08-10 | $23.98M derived: sum of 3 quarters · filed 2023-08-10 | $27.73M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $3.38M 10-Q · filed 2023-05-15 | $23.60M derived: sum of 2 quarters · filed 2023-05-15 | $27.35M derived: sum of 3 quarters · filed 2023-05-15 | $30.90M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $20.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $23.96M derived: sum of 2 quarters · filed 2023-03-14 | $27.51M derived: sum of 3 quarters · filed 2023-03-14 | $30.98M 10-K · filed 2023-03-14 |
| 2021-09-30 | $3.75M 10-Q · filed 2022-11-07 | $7.29M derived: sum of 2 quarters · filed 2022-11-07 | $10.77M 10-Q · filed 2022-11-07 | $10.83M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $3.55M 10-Q · filed 2022-08-11 | $7.02M 10-Q · filed 2022-08-11 | $7.09M derived: sum of 3 quarters · filed 2022-08-11 | $9.92M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $3.47M 10-Q · filed 2022-05-12 | $3.54M derived: sum of 2 quarters · filed 2022-05-12 | $6.37M derived: sum of 3 quarters · filed 2022-05-12 | $9.44M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $2.89M derived: sum of 2 quarters · filed 2022-03-17 | $5.97M derived: sum of 3 quarters · filed 2022-03-17 | $9.19M 10-K · filed 2022-03-17 |
| 2020-09-30 | $2.83M 10-Q · filed 2021-11-10 | $5.90M derived: sum of 2 quarters · filed 2021-11-10 | $9.13M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.07M 10-Q · filed 2021-08-12 | $6.30M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $3.23M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |